Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of
pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed
or progressive disease on or within 6 months of platinum-based chemotherapy.